Ipsen S.A. has acquired Memo Therapeutics AG for €700 million [1] to expand its rare disease treatment pipeline.
The move signals an aggressive growth strategy for the pharmaceutical firm as it seeks to dominate the specialized medicine market. By absorbing Memo Therapeutics AG, Ipsen S.A. gains critical assets that accelerate its ability to bring new therapies to patients with rare conditions.
This transaction marks a period of rapid expansion for the company. It is the second acquisition Ipsen S.A. has completed this month, following the buyout of Kartos on June 29 [4]. The sequence of deals suggests a focused effort to diversify its portfolio through strategic takeovers.
Financial performance has provided the capital necessary for these investments. In its first-quarter results for 2026, Ipsen S.A. reported constant exchange rate (CER) revenue growth of 22.6% [2]. The company's focus on specialized medicine is already yielding results, as rare disease revenues grew by 125% CER [3].
Seeking Alpha said that these strong financial results provided the backdrop for the €700 million [1] investment. The company is leveraging its current liquidity to secure a stronger position in the competitive landscape of rare disease research.
Industry analysts said that the timing of the Memo Therapeutics AG deal, coming so shortly after the Kartos acquisition, demonstrates a high level of urgency in the company's pipeline development. The integration of these two entities will likely reshape the company's research and development priorities for the coming year.
“Ipsen S.A. acquired Memo Therapeutics AG for €700 million”
The rapid-fire acquisition of both Kartos and Memo Therapeutics AG indicates that Ipsen S.A. is shifting from organic growth to an inorganic acquisition model. By utilizing a massive 125% surge in rare disease revenue to fund these deals, the company is attempting to create a moat around its specialized medicine segment, potentially reducing its reliance on broader pharmaceutical markets.
